IDO1 and gastrointestinal stromal tumor: Further, as mentioned before, inhibition of IDO was demonstrated to contribute to the antitumor effects of imatinib in a preclinical model of gastrointestinal stromal tumor by suppressing Tregs and augmenting CD8+ T cells, which were partially induced by imatinib therapy [68].